Nonmetastatic osteosarcoma of the extremity: results of a neoadjuvant chemotherapy protocol (IOR/OS-3) with high-dose methotrexate, intraarterial or intravenous cisplatin, doxorubicin, and salvage chemotherapy based on histologic tumor response.

@article{Ferrari1999NonmetastaticOO,
  title={Nonmetastatic osteosarcoma of the extremity: results of a neoadjuvant chemotherapy protocol (IOR/OS-3) with high-dose methotrexate, intraarterial or intravenous cisplatin, doxorubicin, and salvage chemotherapy based on histologic tumor response.},
  author={Stefano Ferrari and M. Cristina Mercuri and Piero Picci and Franco Bertoni and Adalberto Brach del Prever and Amelia Tienghi and Antonia F Mancini and Alessandra Longhi and Simonetta Rimondini and Davide Donati and M. Manfrini and Pietro Ruggieri and Roberto Biagini and Gaetano Bacci},
  journal={Tumori},
  year={1999},
  volume={85 6},
  pages={458-64}
}
AIMS AND BACKGROUND From 1986 to 1989, a study for the treatment of nonmetastatic osteosarcoma of the extremity (IOR/OS-2) was carried out at the Rizzoli Institute. The cumulative dose of doxorubicin delivered was 480 mg/m2, and severe heart failure developed in 5 (3%) of the 164 treated patients. The specific aim of the subsequent study was to assess the efficacy of a protocol, similar to IOR/OS-2, but with a reduced cumulative dose of doxorubicin (390 mg/m2). Additional aims were to assess… CONTINUE READING
20 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 20 extracted citations

Similar Papers

Loading similar papers…